Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has acquired the global rights to Imukin® (recombinant human interferon gamma-1b) from Horizon Pharma plc (‘Horizon’). Horizon will retain the rights to Actimmune® (recombinant human interferon gamma-1b) in the US, Canada and Japan.
Imukin® is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.
Clinigen will revitalise Imukin® by working with healthcare professionals to ensure its benefits to patients are well understood. The Group will also make the medicine available to those who need it through the Group’s global distribution network for both licensed and unlicensed supply.
Imukin® is the second global acquisition of a biologic by Clinigen following the acquisition of the global rights (outside the US) of Proleukin® from Novartis on 17 July 2018.
Shaun Chilton, Group Chief Executive Officer, Clinigen, said:
“Imukin® strengthens our commercial offering and represents a good strategic fit with our medicines portfolio growth strategy focused on products in oncology and rare diseases.”
David Bryant, Chief Business Officer, Clinigen, said:
“Our second acquisition in recent weeks delivers on our long term strategy of acquiring global rights to assets with the aim of revitalising and returning them back to the broadest possible access.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.